Janssen Biotech announced that Doxil (doxorubucin HCl liposome injection) is available again.
Full access to Doxil injection is restored, and there is no longer a need for the Physician Access Program associated with Doxil C.A.R.E.S (initiated in May 2012). This program is thus being suspended, and healthcare professionals may order Doxil through an authorized distributor. A list of authorized distributors can be found here: www.jom.com/products.html.
Doxil is an anthracycline indicated in AIDS-related Kaposi’s sarcoma refractory to combination chemotherapy, ovarian cancer refractory to platinum-based chemotherapy, and multiple myeloma, in combination with Velcade (bortezomib injection; Millenium), in patients not previously treated with Velcade and who have received at least one prior therapy.
For more information call (866) 298-5774 or visit www.doxil.com.
